Company intelligence / Profile preview

CYTEA BIO

Montpellier, Languedoc-Roussillon, Francecytea.bio ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Completed pre-IND consultation with FDA for CYT-102 with no red flags identified. Also completed EMA "scientific advice" consultation with similar outcome. Expects clinical studies to commence within 15-18 months of closing Series A investment round (as of October 2023).

Therapeutic areas: OncologyImmunology
Modalities: Antibody-effector cell constructsNK cell therapyMonoclonal antibody armed donor NK cells
Industry: Biotech

Drug pipeline

1 asset

CYT-102

Preclinical

Partnerships

EFS Besançon (PIBT)Bionoveo

Beyond the preview

Go deeper on CYTEA BIO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYTEA BIO.

Explore the full profile